Jusmiral Holdings Limited has reduced its stake in Cohance Lifesciences through an open market sale of 34,148,000 shares on September 18, 2025. This sale decreases Jusmiral Holdings’ shareholding to 57.49% of the total share/voting capital. The proceeds from this sale will be used to partially repay borrowings under the Notes Purchase Agreement, disclosed earlier on May 9, 2025.
Stake Reduction Details
On September 18, 2025, Jusmiral Holdings Limited executed an open market sale of 34,148,000 shares in Cohance Lifesciences. This transaction has altered the shareholding structure, as detailed below.
Shareholding Before the Sale
Prior to the sale, Jusmiral Holdings Limited held 25,40,78,170 shares, representing 66.42% of the total share/voting capital.
Post-Sale Shareholding
Following the sale, Jusmiral Holdings Limited now holds 21,99,30,170 shares, which amounts to 57.49% of the total share/voting capital. The company Berhyanda Limited continues to hold 12,75,39,592 equity shares after the sale.
Use of Proceeds
The proceeds from the sale of shares will be primarily used for part payment of borrowings under the Notes Purchase Agreement, previously disclosed on May 9, 2025.
Impact on Total Share Capital
The total equity share capital of Cohance Lifesciences remains at 38,25,67,140 shares. The total diluted share/voting capital after the sale is 38,63,78,339 equity shares.
Source: BSE
